Active Filter(s):
Details:
ISOThrive is studying maltosyl-isomaltooligosaccharide for the treatment of GERD, and potential for reducing risk of Barrett's Esophagus and esophageal adenocarcinoma in collaboration with Eastern VA Medical School, University of VA and George Mason University.
Lead Product(s): Maltosyl-isomaltooligosaccharide
Therapeutic Area: Gastroenterology Product Name: MIMO
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Virginia Catalyst
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 26, 2020